Cantor Fitzgerald Raises Nyxoah (NASDAQ:NYXH) Price Target to $14.00

Nyxoah (NASDAQ:NYXHFree Report) had its target price boosted by Cantor Fitzgerald from $10.00 to $14.00 in a research note issued to investors on Friday morning, Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

A number of other equities research analysts have also recently commented on the company. Piper Sandler raised their price objective on Nyxoah from $10.00 to $15.00 and gave the company an overweight rating in a research note on Thursday, February 1st. HC Wainwright reissued a buy rating and issued a $15.00 target price on shares of Nyxoah in a research report on Monday, December 11th. Finally, Stifel Nicolaus decreased their target price on Nyxoah from $14.00 to $10.00 and set a buy rating for the company in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, Nyxoah currently has an average rating of Moderate Buy and an average price target of $13.50.

Check Out Our Latest Research Report on Nyxoah

Nyxoah Price Performance

Nyxoah stock opened at $12.61 on Friday. The company has a current ratio of 5.55, a quick ratio of 5.43 and a debt-to-equity ratio of 0.10. Nyxoah has a 12 month low of $4.00 and a 12 month high of $12.87. The stock has a 50-day moving average price of $6.14 and a two-hundred day moving average price of $6.60.

Hedge Funds Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NYXH. Invesco Ltd. purchased a new position in Nyxoah during the first quarter worth about $8,177,000. Sei Investments Co. bought a new stake in shares of Nyxoah in the 2nd quarter valued at about $265,000. Millennium Management LLC bought a new stake in shares of Nyxoah in the 4th quarter valued at about $51,000. ExodusPoint Capital Management LP bought a new position in Nyxoah during the 1st quarter valued at approximately $97,000. Finally, AXA S.A. grew its holdings in shares of Nyxoah by 1.4% during the 1st quarter. AXA S.A. now owns 217,000 shares of the company’s stock worth $1,621,000 after acquiring an additional 3,000 shares during the period.

Nyxoah Company Profile

(Get Free Report)

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

Featured Stories

Analyst Recommendations for Nyxoah (NASDAQ:NYXH)

Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.